NCT06234098View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Solid Tumor
Interventions
DRUG

AT-1965 Liposome Injection

AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.

Trial Locations (7)

75230

RECRUITING

CBCC Global Research Site 006, Dallas

85258

RECRUITING

CBCC Global Research Site 001, Scottsdale

90245

RECRUITING

CBCC Global Research Site 007, El Segundo

90403

RECRUITING

CBCC Global Research Site 008, Santa Monica

93309

RECRUITING

CBCC Global Research Site 005, Bakersfield

94305

RECRUITING

CBCC Global Research Site 003, Stanford

97239

RECRUITING

CBCC Global Research Site 002, Portland

Sponsors

Collaborators (1)

CBCC Global Research
All Listed Sponsors
collaborator

CBCC Global Research

NETWORK

lead

Alyssum Therapeutics

INDUSTRY

NCT06234098 - Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter